1418112-79-4

Basic information

• Product Name: 4-chloro-6-((R)-1-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)ethoxy)-2-(4-fluorobenzylthio)pyrimidine
• Synonyms: 4-chloro-6-((R)-1-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)ethoxy)-2-(4-fluorobenzylthio)pyrimidine
• CAS NO: 1418112-79-4
• Molecular Weight: 398.886
• Mol File: 1418112-79-4.mol

Chemical Properties

• CAS DataBase Reference: 4-chloro-6-((R)-1-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)ethoxy)-2-(4-fluorobenzylthio)pyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-chloro-6-((R)-1-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)ethoxy)-2-(4-fluorobenzylthio)pyrimidine(1418112-79-4)
• EPA Substance Registry System: 4-chloro-6-((R)-1-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)ethoxy)-2-(4-fluorobenzylthio)pyrimidine(1418112-79-4)

Safety Data

• Hazardous Substances Data: 1418112-79-4(Hazardous Substances Data)

Upstream product

• 459-46-1 4-Fluorobenzyl bromide 
• 401581-40-6 2-(4-fluorobenzylthio)pyrimidine-4,6-diol 
• 1418112-81-8 (1R)-[1-[(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]ethyl] 3,4,5-trimethoxybenzoate 
• 74134-78-4 (2S,3R)-3,4-epoxy-1,2-O-isopropylidenebutane-1,2-diol 
• 128056-99-5 (S)-1-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)-2-hydroxyethyl 4-methylbenzenesulfonate 
• 166249-17-8 methyl (2R,3S)-3,4-O-isopropylidene-2,3,4-trihydroxy-2-O-(p-toluenesulfonyl)butanoate 
• 92973-40-5 methyl (2R,3S)-3,4-O-isopropylidene-2,3,4-trihydroxybutanoate 
• 92973-39-2 O³,O⁴-(1-methylethylidene)-L-threonic acid 
• 15042-01-0 5,6-O-isopropylidene-L-ascorbic acid 
• 165524-52-7 (R)-1-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)ethan-1-ol 
• 1418112-78-3 4,6-dichloro-2-(4-fluorobenzylthio)pyrimidine 

Downstream Products

• 1418112-77-2 N-(6-{[(2R,3S)-3,4-dihydroxy-2-butanyl]oxy}-2-[(4-fluorobenzyl)sulfanyl]-4-pyrimidinyl)-3-methyl-1-azetidinesulfonamide 
• 1418112-80-7 N-(6-((R)-1-((S)-2,2-dimethyl-1,3-dioxolan-4-yl)ethoxy)-2-(4-fluorobenzyl-thio)pyrimidin-4-yl)-3-methylazetidine-1-sulfonamide 

Relevant articles and documents

CXCR-2 INHIBITORS FOR TREATING CRYSTAL ARTHROPATHY DISORDERS

N-(2-((2,3-difluorobenzyl)thio)-6-(((2R,3S)-3,4-dihydroxybutan-2-yl)oxy)pyrimidin-4-yl)azetidine-1-sulfonamide (compound 3) and N-(6-(((2R,3S)-3,4-dihydroxy butan-2-yl)oxy)-2-((4-fluoro benzyl)thio)pyrimidin-4-yl)-3-methylazetidine-1-sulfonamide(compound 4) are known chemokine modulators and are therefore useful in the treatment of diseases/conditions in which modulation of chemokine receptor activity is beneficial. In particular, provided herein are compositions and methods for the treatment and prevention of gout.

Packaging comprising forms of sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide

The invention relates to a packaging comprising a multitude (A) of at least 2 administration units comprising polymorphic trihydrated forms of sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide; or (B) of at least 2 administration units comprising polymorphic solvated or desolvated forms of sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide.

N- (6- ( (2R,3S) -3,4-DIHYDROXYBUTAN-2-YLOXY) -2- (4 - FLUOROBENZYLTHIO) PYRIMIDIN- 4 - YL) -3- METHYLAZETIDINE- 1 - SULFONAMIDE AS CHEMOKINE RECEPTOR MODULATOR

There is provided a compound which is (a) a pyrimidine sulfonamide of formula (I) or (b) a pharmaceutically acceptable salt thereof, crystalline forms of the compound, processes for obtaining the compound, pharmaceutical intermediates used in the manufacture of the compound, and pharmaceutical compositions containing the compound. The compound is useful in the treatment of a disease/condition in which modulation of chemokine receptor activity is beneficial.